Why insider trading matters?

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

- Peter Lynch
GLYCOMIMETICS INC (GLYC)
Sector: Healthcare; Industry: Biotechnology

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2020-11-04 BVF PARTNERS L P/IL 10%-Owner Buy 1,266,737 $2.60 $3,293,516 No
2020-10-30 BVF PARTNERS L P/IL 10%-Owner Buy 932,612 $2.75 $2,564,683 No
2020-03-09 JUNIUS DANIEL M Director Buy 20,000 $3.40 $68,000 No
2019-09-05 BVF PARTNERS L P/IL 10%-Owner Buy 1,668,746 $3.18 $5,309,950 No
2019-08-13 JUNIUS DANIEL M Director Buy 10,000 $3.18 $31,800 No
2018-10-18 Magnani John L. SVP of Research, CSO Sell 25,000 $14.01 $350,213 No
2018-06-11 Hahn Brian M. CFO Sell 19,345 $18.04 $348,984 Yes
2018-05-10 SANDELL SCOTT D 10%-Owner Sell 9,539 $17.81 $169,890 Yes
2018-05-10 BARRIS PETER J 10%-Owner Sell 9,539 $17.81 $169,890 Yes
2018-05-10 BARRETT M JAMES 10%-Owner, Director Sell 9,539 $17.81 $169,890 Yes
2018-05-10 NEW ENTERPRISE ASSOCIATES 10 L P 10%-Owner Sell 9,539 $17.81 $169,890 Yes
2017-12-08 Thackray Helen M. SVP Clinical Development, CMO Sell 2,000 $15.01 $30,020 No
2017-09-18 Thackray Helen M. SVP Clinical Development, CMO Sell 2,000 $13.00 $26,000 No
2017-05-25 Thackray Helen M. SVP Clinical Development, CMO Sell 2,000 $15.57 $31,140 No
2017-05-19 Thackray Helen M. SVP Clinical Development, CMO Sell 2,000 $12.14 $24,280 No
2016-12-20 JUNIUS DANIEL M Director Buy 5,000 $6.01 $30,050 No
2016-10-03 Thackray Helen M. VP Clinical Development, CMO Sell 4,000 $7.00 $28,001 No
2016-07-20 Thackray Helen M. VP Clinical Development, CMO Sell 2,000 $8.00 $16,000 No
2016-07-06 Thackray Helen M. VP Clinical Development, CMO Sell 22,000 $7.00 $153,954 No
2016-03-04 Goldberg Mark Alan Director Buy 10,397 $4.77 $49,630 No
2015-11-16 SANDELL SCOTT D 10%-Owner Sell 452 $6.91 $3,123 Yes
2015-11-16 BARRIS PETER J 10%-Owner Sell 452 $6.91 $3,123 Yes
2015-11-16 BARRETT M JAMES 10%-Owner, Director Sell 452 $6.91 $3,123 Yes
2015-11-16 NEW ENTERPRISE ASSOCIATES 10 L P 10%-Owner Sell 452 $6.91 $3,123 Yes
2014-12-22 HENOS MICHAEL A Director Sell 21,257 $8.52 $181,190 No
2014-12-17 HENOS MICHAEL A Director Sell 6,725 $8.97 $60,339 Yes
2014-06-13 HENOS MICHAEL A Director Buy 11,000 $6.39 $70,290 No
2014-01-15 BARRIS PETER J 10%-Owner Buy 1,000,000 $8.00 $8,000,000 Yes
2014-01-15 SANDELL SCOTT D 10%-Owner Buy 1,000,000 $8.00 $8,000,000 Yes
2014-01-15 BARRETT M JAMES 10%-Owner, Director Buy 1,000,000 $8.00 $8,000,000 Yes

Insider Smart

MGM Resorts International (MGM) - If we were to pick one of the easy trade from the crash, it has to be MGM, checkout the impressive insider buying after crash. Do you really need more confidence to pull the trigger? That's the mental edge you need to work against fear.

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.